<!DOCTYPE html>
<html lang="fa">
 <meta content="text/html;charset=utf-8" http-equiv="content-type"/>
 <head>
  <title>
   Vulvar cancer: Epidemiology, diagnosis, histopathology, and treatment
  </title>
  <link href="d/css/1.css" rel="stylesheet"/>
 </head>
 <body>
  <!-- Start Main Menu Area -->
  <br/>
  <br/>
  <br/>
  <br/>
  <div class="container">
   <div class="row">
   </div>
  </div>
  <section class="teacher-area ptb-10">
   <div class="container">
   </div>
   <section class="course-details-area ptb-60">
    <div class="container">
     <div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
      <h1 style="text-align:center">
       Vulvar cancer: Epidemiology, diagnosis, histopathology, and treatment
      </h1>
      <div class="utdArticleSection utdStyle" id="topicContent">
       <div id="topicTitle">
        Vulvar cancer: Epidemiology, diagnosis, histopathology, and treatment
       </div>
       <div class="authorSectionElem">
        <div class="authorsElementsLeft">
         <dl id="topicContributors">
          <dt>
           <span>
           </span>
           Authors:
          </dt>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Jonathan S Berek, MD, MMS
           </a>
          </dd>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Amer Karam, MD
           </a>
          </dd>
          <dt>
           <span>
           </span>
           Section Editors:
          </dt>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Barbara Goff, MD
           </a>
          </dd>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Don S Dizon, MD, FACP
           </a>
          </dd>
          <dt>
           <span>
           </span>
           Deputy Editor:
          </dt>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Alana Chakrabarti, MD
           </a>
          </dd>
         </dl>
        </div>
        <div class="authorsElementsRight">
         <div id="literatureReviewDate">
          <div class="litReviewSingleLine">
           <bdi>
            <span class="emphasis">
             Literature review current through:
            </span>
            Jan 2024.
           </bdi>
          </div>
          <div class="litReviewSingleLine">
           <bdi>
            <span class="emphasis">
             This topic last updated:
            </span>
            Jan 26, 2024.
           </bdi>
          </div>
         </div>
        </div>
       </div>
       <div id="topicWhatsNewContainer">
       </div>
       <div id="topicText">
        <p class="headingAnchor" id="H1">
         <span class="h1">
          INTRODUCTION
         </span>
         <span class="headingEndMark">
          —
         </span>
         Vulvar cancer is less common than other gynecologic malignancies, including uterine corpus, ovarian, and cervical cancer; in the United States, vulvar cancer is also less common than vaginal cancer [
         <a href="#rid1">
          1
         </a>
         ]. Squamous cell carcinoma is the most common histologic type of vulvar cancer, comprising at least 75 percent of cases [
         <a href="#rid2">
          2,3
         </a>
         ]. Other histologies include melanoma, basal cell carcinoma, Bartholin gland adenocarcinoma, sarcoma, and Paget disease  (
         <a class="graphic graphic_table graphicRef113829" href="/z/d/graphic/113829.html" rel="external">
          table 1
         </a>
         ).
        </p>
        <p>
         Human papillomavirus (HPV) infection is associated with the majority of vulvar squamous cell carcinomas. In addition, vulvar lichen sclerosus is associated with an increased risk of vulvar cancers.
        </p>
        <p>
         The epidemiology, clinical presentation, diagnosis, and histology of patients with vulvar cancer will be reviewed here. General treatment recommendations are introduced in this topic and discussed in detail elsewhere. Staging, treatment, and prognosis of squamous cell vulvar carcinoma are discussed separately. (See
         <a class="medical medical_review" href="/z/d/html/3248.html" rel="external">
          "Squamous cell carcinoma of the vulva: Staging and surgical treatment"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/108021.html" rel="external">
          "Squamous cell carcinoma of the vulva: Medical therapy and prognosis"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H2">
         <span class="h1">
          EPIDEMIOLOGY
         </span>
         <span class="headingEndMark">
          —
         </span>
         In the United States, there are approximately 6900 new cases of and 1630 deaths from vulvar cancer each year [
         <a href="#rid1">
          1
         </a>
         ].
        </p>
        <p>
         Incidence rates by race or ethnicity in the United States from 2010 to 2014 were: Non-Hispanic White (2.7 per 100,000 persons), non-Hispanic Black (1.8), Asian American/Pacific Islander (0.9), Hispanic American (1.8), and non-Hispanic American (2.6) [
         <a href="#rid4">
          4
         </a>
         ]. In the United States, some data suggest that Black patients present with vulvar cancer at a younger age and have an increased probability of distant spread, which is a consistent finding across the different tumor models [
         <a href="#rid5">
          5,6
         </a>
         ].
        </p>
        <p>
         Females in the United States have a 0.3 percent lifetime risk of being diagnosed with vulvar cancer [
         <a href="#rid4">
          4
         </a>
         ]. The average age of diagnosis of vulvar cancer in the United States is 68 years. The age distribution of cases of vulvar cancer from 2010 to 2014 was:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         &lt;20 years – 0.1 percent
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         20 to 34 years – 1.8 percent
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         35 to 44 – 5.5 percent
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         45 to 54 – 14.6 percent
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         55 to 64 – 20.4 percent
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         65 to 74 – 21.3 percent
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         75 to 84 – 21.4 percent
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         85 or older – 15 percent
        </p>
        <p>
        </p>
        <p>
         Most patients with vulvar cancer are diagnosed at an early stage; the distribution of stage at diagnosis is: confined to primary site (59 percent), spread to regional organs and lymph nodes (30 percent), and distant metastases (6 percent) [
         <a href="#rid4">
          4
         </a>
         ]. In the United States, survival at five years after diagnosis is 72.1 percent; median age at death is 78 years.
        </p>
        <p>
         Squamous cell carcinoma is the most common histologic type of vulvar cancer. Most of the data regarding incidence and prevalence are for vulvar cancer in general, not just squamous cell carcinoma. (See
         <a class="local">
          'Histologic types'
         </a>
         below.)
        </p>
        <p class="headingAnchor" id="H956750412">
         <span class="h1">
          RISK FACTORS AND ETIOLOGY
         </span>
         <span class="headingEndMark">
          —
         </span>
         Risk factors for vulvar cancer include vulvar or cervical intraepithelial neoplasia, a prior history of cervical cancer, cigarette smoking, vulvar lichen sclerosus, immunodeficiency syndromes, and northern European ancestry [
         <a href="#rid7">
          7,8
         </a>
         ].
        </p>
        <p>
         There are two proposed and independent pathways for the development of vulvar squamous cell carcinoma. The first is related to mucosal human papillomavirus (HPV) infection, and the second is related to chronic inflammatory (vulvar dystrophy) or autoimmune processes [
         <a href="#rid9">
          9-12
         </a>
         ]. In a meta-analysis including 92 studies, the prevalence of HPV in vulvar cancer was 39 percent; the most common genotypes were HPV 16 (78 percent) followed by HPV 33 (7.5 percent) [
         <a href="#rid13">
          13
         </a>
         ]. Among those with HPV-positive vulvar cancer, p16
         <sup>
          INK4a
         </sup>
         , a surrogate marker for HPV positivity, was also positive in the majority (73 percent) of cases.
        </p>
        <p>
         For patients with lichen sclerosus, differentiated VIN has been proposed as a precursor lesion to vulvar carcinoma [
         <a href="#rid14">
          14,15
         </a>
         ]. Differentiated VIN is often found in lesions, previously diagnosed as lichen sclerosus, which have progressed to vulvar squamous cell carcinoma. (See
         <a class="medical medical_review" href="/z/d/html/3235.html" rel="external">
          "Vulvar squamous intraepithelial lesions (vulvar intraepithelial neoplasia)", section on 'Risk factors and prevention'
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H3">
         <span class="h1">
          CLINICAL PRESENTATION
         </span>
         <span class="headingEndMark">
          —
         </span>
         Patients with vulvar cancer typically present with a vulvar lesion, noted by the patient or a clinician. The signs and symptoms of all histologic types of vulvar malignancy are similar. Many patients are asymptomatic at the time of diagnosis, but some patients present with vulvar pruritus or bleeding.
        </p>
        <p class="headingAnchor" id="H3128112355">
         <span class="h2">
          Vulvar lesion
         </span>
         <span class="headingEndMark">
          —
         </span>
         Most patients present with a unifocal vulvar plaque, ulcer, or mass (fleshy, nodular, or warty) on the labia majora; the labia minora, perineum, clitoris, and mons are less frequently involved  (
         <a class="graphic graphic_picture graphicRef61663" href="/z/d/graphic/61663.html" rel="external">
          picture 1A
         </a>
         and
         <a class="graphic graphic_picture graphicRef71378" href="/z/d/graphic/71378.html" rel="external">
          picture 1B
         </a>
         and
         <a class="graphic graphic_picture graphicRef50426" href="/z/d/graphic/50426.html" rel="external">
          picture 1C
         </a>
         ). In 10 percent of cases, the lesion is too extensive to determine the actual site of origin  (
         <a class="graphic graphic_picture graphicRef64265" href="/z/d/graphic/64265.html" rel="external">
          picture 1D
         </a>
         and
         <a class="graphic graphic_picture graphicRef130583" href="/z/d/graphic/130583.html" rel="external">
          picture 2
         </a>
         ) [
         <a href="#rid16">
          16
         </a>
         ].
        </p>
        <p>
         Lesions are multifocal in 5 percent of cases; thus, all vulvar and perianal skin surfaces, as well as the cervix and vagina, should be evaluated. A synchronous second malignancy, most commonly cervical neoplasia, is found in up to 22 percent of patients with a vulvar malignancy [
         <a href="#rid17">
          17
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H1369721311">
         <span class="h2">
          Vulvar pruritus
         </span>
         <span class="headingEndMark">
          —
         </span>
         Pruritus is a common complaint associated with many vulvar disorders; it is especially prevalent when there is an underlying vulvar dermatosis (eg, lichen sclerosus or lichen planus)  (
         <a class="graphic graphic_table graphicRef55449" href="/z/d/graphic/55449.html" rel="external">
          table 2
         </a>
         ). (See
         <a class="medical medical_review" href="/z/d/html/5558.html" rel="external">
          "Vulvar lichen sclerosus: Clinical manifestations and diagnosis"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H2464991904">
         <span class="h2">
          Other presentations
         </span>
         <span class="headingEndMark">
          —
         </span>
         Vulvar bleeding or pain may occur in some patients. Dysuria, dyschezia, rectal bleeding, an enlarged lymph node in the groin, or lower-extremity edema are less frequently encountered symptoms and are suggestive of advanced disease.
        </p>
        <p class="headingAnchor" id="H2736883430">
         <span class="h1">
          DIAGNOSTIC EVALUATION
         </span>
         <span class="headingEndMark">
          —
         </span>
         The goal of the diagnostic evaluation is to detect vulvar lesions and determine whether biopsy is indicated. The diagnostic evaluation for vulvar cancer includes:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         A history of risk factors or symptoms associated with vulvar cancer and of factors that may impact treatment.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         A complete pelvic examination, with attention to inspection and palpation of the vulva and groin for lesions, color changes, masses, or ulceration.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Biopsy of grossly visible lesions that raise suspicion of vulvar cancer  (
         <a class="graphic graphic_picture graphicRef61663 graphicRef71378 graphicRef50426 graphicRef64265" href="/z/d/graphic/61663.html" rel="external">
          picture 1A-D
         </a>
         and
         <a class="graphic graphic_picture graphicRef80593" href="/z/d/graphic/80593.html" rel="external">
          picture 3
         </a>
         ). The appearance may vary, and lesions may be single or multiple. Typically, squamous cell carcinoma lesions are firm, white, red, or skin-colored papules, nodules, or plaques. Varying degrees of erosion or ulceration may occur. The surface is often friable. (See
         <a class="medical medical_review" href="/z/d/html/5412.html" rel="external">
          "Vulvar lesions: Differential diagnosis of vesicles, bullae, erosions, and ulcers"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/5450.html" rel="external">
          "Vulvar lesions: Diagnostic evaluation", section on 'Procedure'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Colposcopy of the vulva, if necessary, to identify subclinical lesions not appreciated on gross visual examination. (See
         <a class="medical medical_review" href="/z/d/html/3260.html" rel="external">
          "Colposcopy", section on 'Vulvar colposcopy'
         </a>
         .)
        </p>
        <p>
        </p>
        <p>
         In general, the diagnostic evaluation is similar to that for a patient suspected of vulvar intraepithelial neoplasia. This evaluation is discussed in detail separately. (See
         <a class="medical medical_review" href="/z/d/html/3235.html" rel="external">
          "Vulvar squamous intraepithelial lesions (vulvar intraepithelial neoplasia)", section on 'Diagnostic evaluation'
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H4">
         <span class="h1">
          DIAGNOSIS
         </span>
         <span class="headingEndMark">
          —
         </span>
         Vulvar cancer is a histologic diagnosis made based on a vulvar biopsy. The diagnosis should not be made based on gross or colposcopic appearance only.
        </p>
        <p class="headingAnchor" id="H5">
         <span class="h1">
          DIFFERENTIAL DIAGNOSIS
         </span>
         <span class="headingEndMark">
          —
         </span>
         The differential diagnosis for vulvar cancer includes other vulvar lesions.
        </p>
        <p>
         Vulvar cancer must be differentiated from vulvar intraepithelial neoplasia, which may appear similar or identical to squamous cell vulvar carcinoma and can be differentiated only with biopsy.
        </p>
        <p>
         Vulvar melanoma is rare but is one of the more common nonsquamous histologies of vulvar cancer. There are many etiologies of pigmented lesions of the vulva; common lesions include a melanocytic nevus or angiokeratoma  (
         <a class="graphic graphic_table graphicRef95978" href="/z/d/graphic/95978.html" rel="external">
          table 3
         </a>
         ). Pigmented lesions of the vulva should be examined and evaluated to determine if a biopsy is indicated. The morphology of vulvar melanoma is discussed in detail separately. (See
         <a class="medical medical_review" href="/z/d/html/128408.html" rel="external">
          "Vulvar lesions: Differential diagnosis of pigmented (black, brown, blue) lesions"
         </a>
         .)
        </p>
        <p>
         Vulvar dermatoses that appear as white patches or plaques may also appear similar to vulvar carcinoma. These include lichen sclerosus or lichen planus. (See
         <a class="medical medical_review" href="/z/d/html/5558.html" rel="external">
          "Vulvar lichen sclerosus: Clinical manifestations and diagnosis"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/5557.html" rel="external">
          "Vulvar lichen planus"
         </a>
         .)
        </p>
        <p>
         Other lesions that appear similar to vulvar carcinoma include epidermal inclusion cysts, condyloma acuminata (genital warts), disorders of Bartholin gland, acrochordons, seborrheic keratoses, and hidradenomas. If one of these disorders is initially suspected but does not respond to appropriate treatment, biopsy should be performed.
        </p>
        <p>
         The differential diagnosis of vulvar lesions is discussed in detail separately. (See
         <a class="medical medical_review" href="/z/d/html/5412.html" rel="external">
          "Vulvar lesions: Differential diagnosis of vesicles, bullae, erosions, and ulcers"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H6">
         <span class="h1">
          HISTOLOGIC TYPES
         </span>
         <span class="headingEndMark">
          —
         </span>
         Squamous cell carcinoma is the most common histologic type of vulvar cancer, comprising at least 75 percent or more of cases [
         <a href="#rid2">
          2,3
         </a>
         ]. Other histologies include melanoma, basal cell, Bartholin gland adenocarcinoma, sarcoma, and Paget disease  (
         <a class="graphic graphic_table graphicRef113829" href="/z/d/graphic/113829.html" rel="external">
          table 1
         </a>
         ). The typical distribution of histologies was illustrated in a Dutch cancer registry study from 1989 to 2010 including 5680 patients with vulvar cancer: squamous cell carcinoma (81 percent), basal cell carcinoma (8 percent), melanoma (6 percent), and other histologic subtypes (5 percent) [
         <a href="#rid2">
          2
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H7">
         <span class="h2">
          Squamous cell carcinoma
         </span>
         <span class="headingEndMark">
          —
         </span>
         Seventy-five percent or more of vulvar malignancies are squamous cell carcinomas [
         <a href="#rid2">
          2,3
         </a>
         ]. There are two subtypes, both of which usually occur on the labia or vestibule:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         The keratinizing, differentiated, or simplex type is more common, occurs in older patients, is not related to human papillomavirus (HPV) infection, but is associated with vulvar dystrophies such as lichen sclerosus and, in resource-limited countries, chronic venereal granulomatous disease  (
         <a class="graphic graphic_picture graphicRef130582" href="/z/d/graphic/130582.html" rel="external">
          picture 4
         </a>
         ).
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         The classic, warty, or Bowenoid type is predominantly associated with HPV 16, 18, and 33, and found in younger patients [
         <a href="#rid18">
          18,19
         </a>
         ]. Risk factors associated with HPV infection include early age at first intercourse, multiple sexual partners, HIV infection, and cigarette smoking. These patients tend to present with early-stage disease [
         <a href="#rid20">
          20
         </a>
         ], although several cases of stage III/IV disease in HIV-infected patients have been reported [
         <a href="#rid21">
          21
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         Cervical cancer is also strongly linked to persistent HPV infections [
         <a href="#rid22">
          22
         </a>
         ]. Moreover, there is evidence that some high-grade vulvar and vaginal intraepithelial neoplasias are monoclonal lesions derived from high-grade or malignant cervical disease [
         <a href="#rid23">
          23
         </a>
         ]. Presence of the cervix does not appear to be necessary for oncogenic HPV to infect the genital tract. The prevalence of oncogenic HPV subtypes in the vagina is similar in patients who have and have not undergone hysterectomy [
         <a href="#rid24">
          24
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/8031.html" rel="external">
          "Virology of human papillomavirus infections and the link to cancer"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H8">
         <span class="h3">
          Verrucous carcinoma
         </span>
         <span class="headingEndMark">
          —
         </span>
         Verrucous vulvar carcinoma is a variant of squamous cell carcinoma that has distinctive features. Although cauliflower-like in appearance, it is differentiated from squamous cell carcinoma with a verrucous configuration by biopsy of the lesion base, which shows papillary fronds without the central connective tissue core typical of condylomata acuminata. The lesion grows slowly and rarely metastasizes to lymph nodes, but it may be locally destructive.
        </p>
        <p class="headingAnchor" id="H794362">
         <span class="h2">
          Basal cell carcinoma
         </span>
         <span class="headingEndMark">
          —
         </span>
         Basal cell carcinoma is a squamous histology, but is distinct from squamous cell vulvar carcinoma  (
         <a class="graphic graphic_table graphicRef113829" href="/z/d/graphic/113829.html" rel="external">
          table 1
         </a>
         ). Approximately 2 to 8 percent of vulvar cancers are basal cell cancers, and 2 percent of basal cell cancers occur on the vulva [
         <a href="#rid2">
          2,25
         </a>
         ].
        </p>
        <p>
         Basal cell vulvar carcinoma usually affects postmenopausal White patients and may be locally invasive, although it is usually nonmetastasizing [
         <a href="#rid26">
          26,27
         </a>
         ]. The typical appearance is that of a "rodent" ulcer with rolled edges and central ulceration; the lesion may be pigmented or pearly and gray. It is often asymptomatic, but pruritus, bleeding, or pain may occur.
        </p>
        <p>
         Basal cell carcinomas are associated with a high incidence of antecedent or concomitant malignancy elsewhere in the body [
         <a href="#rid27">
          27
         </a>
         ]. Thus, a thorough search for other primary malignancies should be performed. (See
         <a class="medical medical_review" href="/z/d/html/5335.html" rel="external">
          "Basal cell carcinoma: Epidemiology, pathogenesis, clinical features, and diagnosis"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H9">
         <span class="h2">
          Melanoma
         </span>
         <span class="headingEndMark">
          —
         </span>
         Melanoma is the second most common vulvar cancer histology, accounting for approximately 2 to 10 percent of primary vulvar neoplasms [
         <a href="#rid26">
          26,28-30
         </a>
         ].
        </p>
        <p>
         Melanoma of the vulva occurs predominantly in postmenopausal, non-Hispanic White patients, at a median age of 68 years (range, 10 to 99 years) [
         <a href="#rid29">
          29
         </a>
         ]. By contrast, cutaneous melanomas presenting at other sites often develop before age 45. (See
         <a class="medical medical_review" href="/z/d/html/4844.html" rel="external">
          "Melanoma: Epidemiology and risk factors", section on 'Epidemiology'
         </a>
         .)
        </p>
        <p>
         In a United States national cancer database from 1985 to 1994, female genital tract lesions comprised 0.02 percent of all melanomas and 18 percent of mucosal melanomas [
         <a href="#rid31">
          31
         </a>
         ].
        </p>
        <p>
         Vulvar melanoma is usually a pigmented lesion, but amelanotic lesions also occur. Most arise de novo on the clitoris or labia minora, but can also develop within preexisting junctional or compound nevi [
         <a href="#rid32">
          32
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/128408.html" rel="external">
          "Vulvar lesions: Differential diagnosis of pigmented (black, brown, blue) lesions", section on 'Melanomas'
         </a>
         .)
        </p>
        <p>
         Diagnosis and treatment of vulvar melanoma is discussed in detail elsewhere. (See
         <a class="medical medical_review" href="/z/d/html/7620.html" rel="external">
          "Surgical management of primary cutaneous melanoma or melanoma at other unusual sites"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H11">
         <span class="h2">
          Sarcoma
         </span>
         <span class="headingEndMark">
          —
         </span>
         Soft tissue sarcomas (including leiomyosarcomas, rhabdomyosarcomas, liposarcomas, angiosarcomas, neurofibrosarcomas, epithelioid sarcomas, and undifferentiated/unclassified soft tissue sarcomas) constitute 1 to 2 percent of vulvar malignancies [
         <a href="#rid33">
          33
         </a>
         ]. The prognosis is generally poor [
         <a href="#rid34">
          34,35
         </a>
         ].
        </p>
        <p>
         As with soft tissue sarcomas located elsewhere on the extremities and trunk, high-grade lesions that are larger than 5 cm in diameter, with infiltrating margins and a high mitotic rate, are those most likely to recur. (See
         <a class="medical medical_review" href="/z/d/html/14259.html" rel="external">
          "Clinical presentation, histopathology, diagnostic evaluation, and staging of soft tissue sarcoma", section on 'Histopathology'
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H12">
         <span class="h2">
          Paget disease of the vulva
         </span>
         <span class="headingEndMark">
          —
         </span>
         Extramammary Paget disease, an intraepithelial adenocarcinoma, accounts for less than 1 percent of all vulvar malignancies [
         <a href="#rid36">
          36
         </a>
         ]. Most patients are in their 60s and 70s and are from a White population.
        </p>
        <p>
         Pruritus is the most common symptom, present in 70 percent of patients. Vulvar Paget disease is similar in appearance to Paget disease of the breast (see
         <a class="medical medical_review" href="/z/d/html/814.html" rel="external">
          "Paget disease of the breast (PDB)"
         </a>
         ). The lesion has an eczematoid appearance; it is well demarcated and has slightly raised edges and a red background, often dotted with small, pale islands  (
         <a class="graphic graphic_picture graphicRef130581" href="/z/d/graphic/130581.html" rel="external">
          picture 5
         </a>
         ). It is usually multifocal and may occur anywhere on the vulva, mons, perineum/perianal area, or inner thigh. Extension into the vagina has also been reported [
         <a href="#rid37">
          37
         </a>
         ].
        </p>
        <p>
         Diagnosis is based on characteristic histopathology  (
         <a class="graphic graphic_picture graphicRef62814 graphicRef77680" href="/z/d/graphic/62814.html" rel="external">
          picture 6A-B
         </a>
         ). Vulvar biopsy should be performed in patients with suspicious lesions, including those with persistent pruritic eczematous lesions that fail to resolve within six weeks of appropriate antieczema therapy.
        </p>
        <p>
         Invasive adenocarcinomas may be present within or beneath the surface lesion in up to 25 percent of patients in small series  (
         <a class="graphic graphic_picture graphicRef69564 graphicRef81965" href="/z/d/graphic/69564.html" rel="external">
          picture 7A-B
         </a>
         ) [
         <a href="#rid36">
          36,38-41
         </a>
         ]. Patients with Paget disease of the vulva should also be evaluated for the possibility of synchronous neoplasms, as approximately 20 to 30 percent of these patients have a noncontiguous carcinoma (eg, involving breast, rectum, bladder, urethra, cervix, or ovary) [
         <a href="#rid42">
          42
         </a>
         ]. Evaluation may include mammography, colonoscopy, urine cytology, and/or transvaginal ultrasound [
         <a href="#rid43">
          43
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H13">
         <span class="h2">
          Bartholin gland carcinoma
         </span>
         <span class="headingEndMark">
          —
         </span>
         Bartholin gland carcinoma comprises approximately 0.1 to 5 percent of all vulvar carcinomas and 0.001 percent of all female malignancies [
         <a href="#rid44">
          44
         </a>
         ]. The incidence of Bartholin gland carcinoma in one series was 0.023 per 100,000 person-years in premenopausal patients and 0.114 per 100,000 person-years in postmenopausal patients [
         <a href="#rid45">
          45
         </a>
         ]. The incidence of Bartholin gland carcinoma is highest among patients in their 60s. Most affected patients do not have a past history of benign Bartholin gland disorders.
        </p>
        <p>
         Cancers arising in the Bartholin gland are most often adenocarcinomas or squamous cell carcinomas, but transitional cell carcinomas, adenosquamous, and adenoid cystic carcinomas may also develop [
         <a href="#rid46">
          46,47
         </a>
         ]. Most primary adenocarcinomas of the vulva occur in the Bartholin gland. Only the squamous cell carcinomas of the Bartholin gland are related to HPV infection [
         <a href="#rid46">
          46
         </a>
         ].
        </p>
        <p>
         Metastatic disease is common in cancers of the Bartholin gland because of the rich vascular and lymphatic network in this area. In one series of 11 patients with Bartholin gland cancer, 55 percent developed recurrent disease, and 67 percent were alive at five years [
         <a href="#rid48">
          48
         </a>
         ]. The only two patients with isolated vulvar recurrence were alive without disease at 8 and 180 months, respectively.
        </p>
        <p>
         Differentiating Bartholin gland carcinoma from benign Bartholin gland masses is discussed separately.
        </p>
        <p class="headingAnchor" id="H945507468">
         <span class="h1">
          TREATMENT
         </span>
        </p>
        <p class="headingAnchor" id="H701369679">
         <span class="h2">
          Squamous cell carcinoma
         </span>
         <span class="headingEndMark">
          —
         </span>
         The treatment of vulvar squamous cell carcinoma depends on both the extent of the vulvar lesion and the lymph node evaluation and is described in detail elsewhere. (See
         <a class="medical medical_review" href="/z/d/html/3248.html" rel="external">
          "Squamous cell carcinoma of the vulva: Staging and surgical treatment"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/108021.html" rel="external">
          "Squamous cell carcinoma of the vulva: Medical therapy and prognosis"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H3930986225">
         <span class="h2">
          Verrucous carcinoma
         </span>
         <span class="headingEndMark">
          —
         </span>
         Radical local excision is usually adequate as verrucous carcinoma is locally invasive, but rarely metastasizes. Suspicious lymph nodes should be biopsied; if positive, then inguinofemoral lymphadenectomy is indicated. Radiation therapy (RT) is thought to be contraindicated because it is thought to induce anaplastic transformation and increase the likelihood of metastases, but the evidence for this is sparse. Recurrences are usually treated surgically.
        </p>
        <p class="headingAnchor" id="H1994602896">
         <span class="h2">
          Basal cell carcinoma
         </span>
         <span class="headingEndMark">
          —
         </span>
         Basal cell carcinomas are locally aggressive, but rarely metastasize. Therefore, radical local excision without lymphadenectomy is adequate. (See
         <a class="medical medical_review" href="/z/d/html/5338.html" rel="external">
          "Treatment and prognosis of basal cell carcinoma at low risk of recurrence"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H2883273328">
         <span class="h2">
          Melanoma
         </span>
         <span class="headingEndMark">
          —
         </span>
         The treatment of vulvar melanoma is discussed elsewhere. (See
         <a class="medical medical_review" href="/z/d/html/16904.html" rel="external">
          "Locoregional mucosal melanoma: Epidemiology, clinical diagnosis, and treatment", section on 'Vulvovaginal melanoma'
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H197128086">
         <span class="h2">
          Sarcoma
         </span>
         <span class="headingEndMark">
          —
         </span>
         Among the more common histologic types are angiomyxoma [
         <a href="#rid49">
          49
         </a>
         ] and rhabdomyosarcoma; the latter is typically diagnosed in children [
         <a href="#rid50">
          50
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/7721.html" rel="external">
          "Rhabdomyosarcoma in childhood, adolescence, and adulthood: Treatment", section on 'Role of surgery'
         </a>
         .)
        </p>
        <p>
         Wide local excision is the standard approach to treatment of most vulvar sarcomas. Lymphatic metastases are uncommon [
         <a href="#rid49">
          49,51
         </a>
         ] (see
         <a class="medical medical_review" href="/z/d/html/7721.html" rel="external">
          "Rhabdomyosarcoma in childhood, adolescence, and adulthood: Treatment", section on 'Role of surgery'
         </a>
         ). Surgical treatment is often accompanied by preoperative or postoperative radiation in analogy to the treatment of extremity and truncal soft tissue sarcomas at anatomic sites where wide surgical margins cannot be obtained absent major, debilitating sequelae such as limb amputation.
        </p>
        <p class="headingAnchor" id="H4158696707">
         <span class="h2">
          Paget disease of the vulva
         </span>
         <span class="headingEndMark">
          —
         </span>
         The vulva is one of the most common sites for extramammary Paget disease. Treatment typically consists of wide local excision or vulvectomy, depending on the extent of disease, though more conservative surgery has been described in selected patients (eg, older patients, poor performance status) [
         <a href="#rid52">
          52
         </a>
         ]. Radical excision is not required, but a 2 cm margin is preferred. Greater depth of invasion and lymphovascular involvement are poor prognostic markers [
         <a href="#rid51">
          51
         </a>
         ]. Some have suggested that inguinal lymphadenectomy be performed in cases with invasive disease or an underlying adenocarcinoma [
         <a href="#rid53">
          53
         </a>
         ].
        </p>
        <p>
         Twelve to 58 percent of patients experience a local recurrence, which may occur despite negative surgical margins, presumably because of multicentricity and microscopic extension of disease beyond the clinically visible margins [
         <a href="#rid38">
          38,39,54
         </a>
         ]. It may require a margin of 5 cm of normal-appearing skin from the visible tumor margin to obtain microscopically clear margins [
         <a href="#rid55">
          55
         </a>
         ]. Use of
         <a class="drug drug_general" data-topicid="8461" href="/z/d/drug information/8461.html" rel="external">
          fluorescein
         </a>
         mapping [
         <a href="#rid56">
          56
         </a>
         ] or Mohs micrographic surgery (ie, microscopically controlled systematic excision of cancerous tissue) may be associated with lower recurrence rates, particularly for recurrent tumors [
         <a href="#rid51">
          51,55,57,58
         </a>
         ]. A full description of the technique of Mohs micrographic surgery is found separately. (See
         <a class="medical medical_review" href="/z/d/html/13708.html" rel="external">
          "Mohs surgery"
         </a>
         .)
        </p>
        <p>
         There are no data addressing the benefit of adjuvant RT. The roles of definitive RT, cytotoxic chemotherapy, and topical
         <a class="drug drug_general" data-topicid="8638" href="/z/d/drug information/8638.html" rel="external">
          imiquimod
         </a>
         in the treatment of Paget disease of the vulva are also not well defined, but may be an option for some patients [
         <a href="#rid51">
          51,59-66
         </a>
         ]. Overexpression of the human epidermal growth factor receptor 2 (HER2) has been reported [
         <a href="#rid67">
          67,68
         </a>
         ].
        </p>
        <p>
         Long-term follow-up is indicated because of the high risk of recurrence and the increased risk of noncontiguous carcinoma. Paget disease is associated with underlying invasive adenocarcinomas in up to 25 percent of patients [
         <a href="#rid36">
          36,38-41
         </a>
         ], and another 20 to 30 percent will have or will develop an adenocarcinoma at another nonvulvar location [
         <a href="#rid36">
          36,38
         </a>
         ]. In one series, 8 percent of patients with noninvasive vulvar Paget disease progressed to invasive vulvar disease after a median of five years, but some or all of these cases may represent a de novo invasive lesion rather than progression of noninvasive disease [
         <a href="#rid39">
          39
         </a>
         ]. The vulva should be inspected annually with a low threshold for biopsy. Screening and surveillance for tumors at other sites (breast, lung, colorectum, gastric, pancreas, and ovary) should be considered. (See
         <a class="medical medical_review" href="/z/d/html/7564.html" rel="external">
          "Screening for breast cancer: Strategies and recommendations"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/7565.html" rel="external">
          "Screening for colorectal cancer: Strategies in patients at average risk"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H3087178734">
         <span class="h2">
          Bartholin gland carcinoma
         </span>
         <span class="headingEndMark">
          —
         </span>
         Primary carcinoma of the Bartholin gland is rare, comprising approximately 0.1 to 5 percent of all vulvar carcinomas and 0.001 percent of all female malignancies [
         <a href="#rid44">
          44
         </a>
         ]. The incidence of Bartholin gland carcinoma in one series was 0.023 per 100,000 person-years in premenopausal patients and 0.114 per 100,000 person-years in postmenopausal patients [
         <a href="#rid45">
          45
         </a>
         ]. The incidence is highest among those in their 60s. Most affected patients do not have a past history of benign Bartholin gland disorders.
        </p>
        <p>
         Approximately 50 percent of Bartholin gland carcinomas are of squamous histology and are thought to originate in the Bartholin duct rather than the gland. The remainder includes a variety of rare adenocarcinomas including adenoid/cystic carcinomas whose indolent natural history, proclivity for perineural invasion, and infrequent spread to lymph nodes mimic the behavior of adenoid/cystic carcinomas of the salivary glands [
         <a href="#rid69">
          69,70
         </a>
         ].
        </p>
        <p>
         Bartholin gland carcinoma is typically deep within the vulva  (
         <a class="graphic graphic_figure graphicRef66162" href="/z/d/graphic/66162.html" rel="external">
          figure 1
         </a>
         ), and diagnosis is often delayed since findings on gross examination appear late in the course of the disease. The most common presentation is as a painless vulvar mass, and a mass in the Bartholin complex is often misdiagnosed as an abscess or cyst. The mass may be solid, cystic, or abscessed, or a solid area may be palpated within a Bartholin cyst. Fixation to underlying tissue is suspicious for malignancy. Extension to the overlying skin is a late manifestation, and extension through the Bartholin duct to the vagina with subsequent bleeding usually occurs only in the setting of bulky disease.
        </p>
        <p>
         A complete excision of disease often requires an extensive and deep dissection. The traditional approach to therapy is radical vulvectomy with bilateral groin and pelvic lymphadenectomy. Less radical excisions, such as radical local excision or partial vulvectomy with ipsilateral inguinal lymphadenectomy, also appear to be effective [
         <a href="#rid47">
          47,71
         </a>
         ]. Surgical margins are frequently microscopically positive because of proximity of the primary to the anorectum and pubic arch and require postoperative RT to reduce the incidence of local recurrence [
         <a href="#rid47">
          47
         </a>
         ].
        </p>
        <p>
         Primary chemoradiotherapy or brachytherapy are therapeutic options that may allow sparing of rectal function or obviate the need for surgery entirely in patients with primary carcinoma of the Bartholin gland [
         <a href="#rid72">
          72-75
         </a>
         ]. Chemoradiation may be particularly effective in cancers with squamous histology. If ipsilateral groin nodes are involved, pelvic and bilateral groin radiation may decrease the frequency of regional recurrence. For advanced disease, single case reports describe activity for
         <a class="drug drug_general" data-topicid="10135" href="/z/d/drug information/10135.html" rel="external">
          pegylated liposomal doxorubicin
         </a>
         [
         <a href="#rid61">
          61
         </a>
         ] and
         <a class="drug drug_general" data-topicid="9735" href="/z/d/drug information/9735.html" rel="external">
          paclitaxel
         </a>
         [
         <a href="#rid76">
          76
         </a>
         ].
        </p>
        <p>
         Metastatic disease is common in cancers of the Bartholin gland because of the rich vascular and lymphatic network of the vulva. Nevertheless, a study summarizing 30 years' clinical experience and involving 36 patients with Bartholin carcinoma reported a five-year survival rate of 85 percent [
         <a href="#rid47">
          47
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H2161654220">
         <span class="h1">
          SOCIETY GUIDELINE LINKS
         </span>
         <span class="headingEndMark">
          —
         </span>
         Links to society and government-sponsored guidelines from selected countries and regions around the world are provided separately. (See
         <a class="medical medical_society_guidelines" href="/z/d/html/113636.html" rel="external">
          "Society guideline links: Vulvar cancer and vaginal cancer"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H15">
         <span class="h1">
          SUMMARY AND RECOMMENDATIONS
         </span>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Epidemiology
         </strong>
         – Vulvar cancer is the fourth most common gynecologic malignancy in the United States (after uterine, ovarian, and cervical). There are approximately 6000 cases and 1000 deaths from the disease each year. (See
         <a class="local">
          'Epidemiology'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         Females in the United States have an 0.3 percent lifetime risk of being diagnosed with vulvar cancer. The average age of diagnosis of vulvar cancer is 68 years. Most patients with vulvar cancer are diagnosed at an early stage (approximately 60 percent are confined to primary site). Survival at five years after diagnosis is 72.1 percent; median age at death is 78 years. (See
         <a class="local">
          'Epidemiology'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Histologic types
         </strong>
         – Squamous cell carcinoma is the most common histologic type of vulvar cancer, comprising at least 75 percent or more of cases [
         <a href="#rid2">
          2,3
         </a>
         ]. Other histologies include melanoma, basal cell carcinoma, Bartholin gland adenocarcinoma, sarcoma, and Paget disease  (
         <a class="graphic graphic_table graphicRef113829" href="/z/d/graphic/113829.html" rel="external">
          table 1
         </a>
         ). (See
         <a class="local">
          'Epidemiology'
         </a>
         above and
         <a class="local">
          'Histologic types'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Risk factors
         </strong>
         – Risk factors for vulvar cancer include vulvar or cervical intraepithelial neoplasia, a prior history of cervical cancer, cigarette smoking, vulvar lichen sclerosus, and immunodeficiency syndromes. Squamous cell carcinoma of the vulva has two proposed pathogenic pathways: human papillomavirus (HPV) infection and chronic inflammatory or autoimmune processes. (See
         <a class="local">
          'Risk factors and etiology'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Clinical presentation
         </strong>
         – Patients with vulvar cancer typically present with a vulvar lesion, noted by the patient or a clinician. Many patients are asymptomatic at the time of diagnosis, but some patients present with vulvar pruritus or bleeding. A complaint of a groin mass or urinary or lower gastrointestinal tract symptoms are associated with advanced disease. (See
         <a class="local">
          'Clinical presentation'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Diagnosis
         </strong>
         – Vulvar cancer is a histologic diagnosis and is made based on biopsy of a vulvar lesion. The goal of the diagnostic evaluation is to detect vulvar lesions and determine whether biopsy is indicated. The evaluation includes eliciting a history of vulvar cancer symptoms and risk factors, pelvic examination with careful examination to detect and characterize lesions, possible colposcopy, and biopsy. (See
         <a class="local">
          'Diagnosis'
         </a>
         above and
         <a class="local">
          'Diagnostic evaluation'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Differential diagnosis
         </strong>
         – The differential diagnosis includes other vulvar lesions with a similar appearance. The appearance of vulvar cancers varies. Typically, squamous cell lesions are firm, white, red, or skin-colored papules, nodules, or plaques. Varying degrees of erosion or ulceration may occur. The surface is often friable. Melanoma is a pigmented lesion. The differential diagnosis includes vulvar intraepithelial neoplasia, melanocytic nevus, angiokeratoma, lichen sclerosus, and condyloma acuminata (genital warts). (See
         <a class="local">
          'Differential diagnosis'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Management
         </strong>
         – General treatment principles for vulvar cancer are introduced in this topic and discussed in detail elsewhere. (See
         <a class="local">
          'Treatment'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H475501346">
         <span class="h1">
          ACKNOWLEDGMENT
         </span>
         <span class="headingEndMark">
          —
         </span>
         The UpToDate editorial staff acknowledges John C Elkas, MD, JD, who contributed to previous versions of this topic review.
        </p>
       </div>
       <div class="headingAnchor" id="references">
        <ol id="reference">
         <li>
          <a class="nounderline abstract_t">
           Siegel RL, Giaquinto AN, Jemal A. Cancer statistics, 2024. CA Cancer J Clin 2024; 74:12.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Schuurman MS, van den Einden LC, Massuger LF, et al. Trends in incidence and survival of Dutch women with vulvar squamous cell carcinoma. Eur J Cancer 2013; 49:3872.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Saraiya M, Watson M, Wu X, et al. Incidence of in situ and invasive vulvar cancer in the US, 1998-2003. Cancer 2008; 113:2865.
          </a>
         </li>
         <li class="breakAll">
          https://seer.cancer.gov/statfacts/html/vulva.html (Accessed on April 28, 2017).
         </li>
         <li>
          <a class="nounderline abstract_t">
           Rauh-Hain JA, Clemmer JT, Bradford LS, et al. Racial disparities in cervical cancer survival over time. Cancer 2013; 119:3644.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Jagsi R, Abrahamse P, Hawley ST, et al. Underascertainment of radiotherapy receipt in Surveillance, Epidemiology, and End Results registry data. Cancer 2012; 118:333.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Madsen BS, Jensen HL, van den Brule AJ, et al. Risk factors for invasive squamous cell carcinoma of the vulva and vagina--population-based case-control study in Denmark. Int J Cancer 2008; 122:2827.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Brinton LA, Thistle JE, Liao LM, Trabert B. Epidemiology of vulvar neoplasia in the NIH-AARP Study. Gynecol Oncol 2017; 145:298.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           de Koning MN, Quint WG, Pirog EC. Prevalence of mucosal and cutaneous human papillomaviruses in different histologic subtypes of vulvar carcinoma. Mod Pathol 2008; 21:334.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Halec G, Alemany L, Quiros B, et al. Biological relevance of human papillomaviruses in vulvar cancer. Mod Pathol 2017; 30:549.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Weberpals JI, Lo B, Duciaume MM, et al. Vulvar Squamous Cell Carcinoma (VSCC) as Two Diseases: HPV Status Identifies Distinct Mutational Profiles Including Oncogenic Fibroblast Growth Factor Receptor 3. Clin Cancer Res 2017; 23:4501.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           de Sanjosé S, Alemany L, Ordi J, et al. Worldwide human papillomavirus genotype attribution in over 2000 cases of intraepithelial and invasive lesions of the vulva. Eur J Cancer 2013; 49:3450.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Li Z, Liu P, Wang Z, et al. Prevalence of human papillomavirus DNA and p16INK4a positivity in vulvar cancer and vulvar intraepithelial neoplasia: a systematic review and meta-analysis. Lancet Oncol 2023; 24:403.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           van de Nieuwenhof HP, Bulten J, Hollema H, et al. Differentiated vulvar intraepithelial neoplasia is often found in lesions, previously diagnosed as lichen sclerosus, which have progressed to vulvar squamous cell carcinoma. Mod Pathol 2011; 24:297.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Bigby SM, Eva LJ, Fong KL, Jones RW. The Natural History of Vulvar Intraepithelial Neoplasia, Differentiated Type: Evidence for Progression and Diagnostic Challenges. Int J Gynecol Pathol 2016; 35:574.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Zacur H, Genadry R, Woodruff JD. The patient-at-risk for development of vulvar cancer. Gynecol Oncol 1980; 9:199.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Collins CG, Lee FY, Roman-Lopez JJ. Invasive carcinoma of the vulva with lymph node metastasis. Am J Obstet Gynecol 1971; 109:446.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Hildesheim A, Han CL, Brinton LA, et al. Human papillomavirus type 16 and risk of preinvasive and invasive vulvar cancer: results from a seroepidemiological case-control study. Obstet Gynecol 1997; 90:748.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Iwasawa A, Nieminen P, Lehtinen M, Paavonen J. Human papillomavirus in squamous cell carcinoma of the vulva by polymerase chain reaction. Obstet Gynecol 1997; 89:81.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Al-Ghamdi A, Freedman D, Miller D, et al. Vulvar squamous cell carcinoma in young women: a clinicopathologic study of 21 cases. Gynecol Oncol 2002; 84:94.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Elit L, Voruganti S, Simunovic M. Invasive vulvar cancer in a woman with human immunodeficiency virus: case report and review of the literature. Gynecol Oncol 2005; 98:151.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Bosch FX, Manos MM, Muñoz N, et al. Prevalence of human papillomavirus in cervical cancer: a worldwide perspective. International biological study on cervical cancer (IBSCC) Study Group. J Natl Cancer Inst 1995; 87:796.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Vinokurova S, Wentzensen N, Einenkel J, et al. Clonal history of papillomavirus-induced dysplasia in the female lower genital tract. J Natl Cancer Inst 2005; 97:1816.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Castle PE, Schiffman M, Bratti MC, et al. A population-based study of vaginal human papillomavirus infection in hysterectomized women. J Infect Dis 2004; 190:458.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           de Giorgi V, Salvini C, Massi D, et al. Vulvar basal cell carcinoma: retrospective study and review of literature. Gynecol Oncol 2005; 97:192.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Piura B, Rabinovich A, Dgani R. Basal cell carcinoma of the vulva. J Surg Oncol 1999; 70:172.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Benedet JL, Miller DM, Ehlen TG, Bertrand MA. Basal cell carcinoma of the vulva: clinical features and treatment results in 28 patients. Obstet Gynecol 1997; 90:765.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Piura B, Egan M, Lopes A, Monaghan JM. Malignant melanoma of the vulva: a clinicopathologic study of 18 cases. J Surg Oncol 1992; 50:234.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Sugiyama VE, Chan JK, Shin JY, et al. Vulvar melanoma: a multivariable analysis of 644 patients. Obstet Gynecol 2007; 110:296.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Stang A, Streller B, Eisinger B, Jöckel KH. Population-based incidence rates of malignant melanoma of the vulva in Germany. Gynecol Oncol 2005; 96:216.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Chang AE, Karnell LH, Menck HR. The National Cancer Data Base report on cutaneous and noncutaneous melanoma: a summary of 84,836 cases from the past decade. The American College of Surgeons Commission on Cancer and the American Cancer Society. Cancer 1998; 83:1664.
          </a>
         </li>
         <li class="breakAll">
          Berek JS, Hacker NF. Berek &amp; Hacker’s Gynecologic Oncology, 7th ed., Wolters Kluwer, 2021.
         </li>
         <li>
          <a class="nounderline abstract_t">
           Johnson S, Renz M, Wheeler L, et al. Vulvar sarcoma outcomes by histologic subtype: a Surveillance, Epidemiology, and End Results (SEER) database review. Int J Gynecol Cancer 2020; 30:1118.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Han CH, Li X, Khanna N. Epithelioid sarcoma of the vulva and its clinical implication: A case report and review of the literature. Gynecol Oncol Rep 2016; 15:31.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Nasioudis D, Alevizakos M, Chapman-Davis E, et al. Rhabdomyosarcoma of the lower female genital tract: an analysis of 144 cases. Arch Gynecol Obstet 2017; 296:327.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Parker LP, Parker JR, Bodurka-Bevers D, et al. Paget's disease of the vulva: pathology, pattern of involvement, and prognosis. Gynecol Oncol 2000; 77:183.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Kown BS, Ji YI, Jung MH, Kim YS. Total vaginectomy and radical vulvectomy for extension of extra-mammary Paget's disease. Eur J Gynaecol Oncol 2016; 37:861.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Fanning J, Lambert HC, Hale TM, et al. Paget's disease of the vulva: prevalence of associated vulvar adenocarcinoma, invasive Paget's disease, and recurrence after surgical excision. Am J Obstet Gynecol 1999; 180:24.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           van der Linden M, Oonk MHM, van Doorn HC, et al. Vulvar Paget disease: A national retrospective cohort study. J Am Acad Dermatol 2019; 81:956.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Cai Y, Sheng W, Xiang L, et al. Primary extramammary Paget's disease of the vulva: the clinicopathological features and treatment outcomes in a series of 43 patients. Gynecol Oncol 2013; 129:412.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Jones IS, Crandon A, Sanday K. Paget's disease of the vulva: Diagnosis and follow-up key to management; a retrospective study of 50 cases from Queensland. Gynecol Oncol 2011; 122:42.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Feuer GA, Shevchuk M, Calanog A. Vulvar Paget's disease: the need to exclude an invasive lesion. Gynecol Oncol 1990; 38:81.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Kibbi N, Owen JL, Worley B, et al. Evidence-Based Clinical Practice Guidelines for Extramammary Paget Disease. JAMA Oncol 2022; 8:618.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           DePasquale SE, McGuinness TB, Mangan CE, et al. Adenoid cystic carcinoma of Bartholin's gland: a review of the literature and report of a patient. Gynecol Oncol 1996; 61:122.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Visco AG, Del Priore G. Postmenopausal bartholin gland enlargement: a hospital-based cancer risk assessment. Obstet Gynecol 1996; 87:286.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Felix JC, Cote RJ, Kramer EE, et al. Carcinomas of Bartholin's gland. Histogenesis and the etiological role of human papillomavirus. Am J Pathol 1993; 142:925.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Copeland LJ, Sneige N, Gershenson DM, et al. Bartholin gland carcinoma. Obstet Gynecol 1986; 67:794.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Cardosi RJ, Speights A, Fiorica JV, et al. Bartholin's gland carcinoma: a 15-year experience. Gynecol Oncol 2001; 82:247.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Fine BA, Munoz AK, Litz CE, Gershenson DM. Primary medical management of recurrent aggressive angiomyxoma of the vulva with a gonadotropin-releasing hormone agonist. Gynecol Oncol 2001; 81:120.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Martelli H, Oberlin O, Rey A, et al. Conservative treatment for girls with nonmetastatic rhabdomyosarcoma of the genital tract: A report from the Study Committee of the International Society of Pediatric Oncology. J Clin Oncol 1999; 17:2117.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Shepherd V, Davidson EJ, Davies-Humphreys J. Extramammary Paget's disease. BJOG 2005; 112:273.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Seo T, Kitamura S, Yanagi T, et al. Prognostic Analysis of Patients With Extramammary Paget Disease Treated With Conservative Excision. Dermatol Surg 2023; 49:743.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Niikura H, Yoshida H, Ito K, et al. Paget's disease of the vulva: clinicopathologic study of type 1 cases treated at a single institution. Int J Gynecol Cancer 2006; 16:1212.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Tebes S, Cardosi R, Hoffman M. Paget's disease of the vulva. Am J Obstet Gynecol 2002; 187:281.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Hendi A, Brodland DG, Zitelli JA. Extramammary Paget's disease: surgical treatment with Mohs micrographic surgery. J Am Acad Dermatol 2004; 51:767.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Wagar MK, Zhang RC, Weisman P, et al. Fluorescein Mapping in Vulvar Paget Disease. Obstet Gynecol 2023; 141:608.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Zollo JD, Zeitouni NC. The Roswell Park Cancer Institute experience with extramammary Paget's disease. Br J Dermatol 2000; 142:59.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           O'Connor WJ, Lim KK, Zalla MJ, et al. Comparison of mohs micrographic surgery and wide excision for extramammary Paget's disease. Dermatol Surg 2003; 29:723.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Yokoyama Y, Mabuchi M, Kawabata I, et al. Metastatic vulvar Paget's disease responding to combination chemotherapy: case report. Jpn J Clin Oncol 1990; 20:426.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Yamamoto R, Sakuragi N, Shirato H, et al. Radiotherapy with concurrent chemotherapy for vulvar adenocarcinoma associated with extramammary Paget's disease. Gynecol Oncol 2001; 80:267.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Huang GS, Juretzka M, Ciaravino G, et al. Liposomal doxorubicin for treatment of metastatic chemorefractory vulvar adenocarcinoma. Gynecol Oncol 2002; 87:313.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Hatch KD, Davis JR. Complete resolution of Paget disease of the vulva with imiquimod cream. J Low Genit Tract Dis 2008; 12:90.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Son SH, Lee JS, Kim YS, et al. The role of radiation therapy for the extramammary paget's disease of the vulva ; experience of 3 cases. Cancer Res Treat 2005; 37:365.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Sendagorta E, Herranz P, Feito M, et al. Successful treatment of three cases of primary extramammary Paget's disease of the vulva with Imiquimod--proposal of a therapeutic schedule. J Eur Acad Dermatol Venereol 2010; 24:490.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Hata M, Omura M, Koike I, et al. Role of radiotherapy as curative treatment of extramammary Paget's disease. Int J Radiat Oncol Biol Phys 2011; 80:47.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Pyle HJ, Goff HW, Nwachukwu CR, Mauskar MM. Treatment-refractory extramammary Paget disease responsive to radiotherapy. Am J Obstet Gynecol 2022; 226:852.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Brummer O, Stegner HE, Böhmer G, et al. HER-2/neu expression in Paget disease of the vulva and the female breast. Gynecol Oncol 2004; 95:336.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Richter CE, Hui P, Buza N, et al. HER-2/NEU overexpression in vulvar Paget disease: the Yale experience. J Clin Pathol 2010; 63:544.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Alsan CI, Vinh-Hung V, Eren F, Abacioğlu U. Adenoid cystic carcinoma of the Bartholin's gland: case report and systematic review of the literature. Eur J Gynaecol Oncol 2011; 32:567.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Kozakiewicz B, Dmoch-Gajzlerska E, Roszkowska-Purska K. Carcinomas and sarcomas of Bartholin gland. A report of nine cases and review of the literature. Eur J Gynaecol Oncol 2014; 35:243.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Balat O, Edwards CL, Delclos L. Advanced primary carcinoma of the Bartholin gland: report of 18 patients. Eur J Gynaecol Oncol 2001; 22:46.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Massad LS, De Geest K. Multimodality therapy for carcinoma of the Bartholin gland. Gynecol Oncol 1999; 75:305.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Yamada T, Yanagawa S, Iwai H, et al. High-dose-rate interstitial brachytherapy of Bartholin's gland: A case report. Gynecol Oncol 2000; 77:193.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           López-Varela E, Oliva E, McIntyre JF, Fuller AF Jr. Primary treatment of Bartholin's gland carcinoma with radiation and chemoradiation: a report on ten consecutive cases. Int J Gynecol Cancer 2007; 17:661.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Downs LS, Ghosh K, Dusenbery KE, Cosin JA. Stage IV carcinoma of the Bartholin gland managed with primary chemoradiation. Gynecol Oncol 2002; 87:210.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Tanaka H, Umekawa T, Nagao K, et al. Adenocarcinoma of mammary-like glands in the vulva successfully treated by weekly paclitaxel. Int J Gynecol Cancer 2005; 15:568.
          </a>
         </li>
        </ol>
       </div>
       <div id="topicVersionRevision">
        Topic 3237 Version 45.0
       </div>
      </div>
      <div class="row">
       <div class="col-12">
        <h4 style="text-align: center;padding: 20px;color: cadetblue;">
         References
        </h4>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/38230766" id="rid0" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          1 : Cancer statistics, 2024.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/24011936" id="rid1" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          2 : Trends in incidence and survival of Dutch women with vulvar squamous cell carcinoma.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/18980209" id="rid2" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          3 : Incidence of in situ and invasive vulvar cancer in the US, 1998-2003.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/18980209" id="rid3" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          4 : Incidence of in situ and invasive vulvar cancer in the US, 1998-2003.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/23913530" id="rid4" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          5 : Racial disparities in cervical cancer survival over time.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/21717446" id="rid5" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          6 : Underascertainment of radiotherapy receipt in Surveillance, Epidemiology, and End Results registry data.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/18348142" id="rid6" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          7 : Risk factors for invasive squamous cell carcinoma of the vulva and vagina--population-based case-control study in Denmark.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/28236455" id="rid7" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          8 : Epidemiology of vulvar neoplasia in the NIH-AARP Study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/18192968" id="rid8" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          9 : Prevalence of mucosal and cutaneous human papillomaviruses in different histologic subtypes of vulvar carcinoma.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/28059099" id="rid9" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          10 : Biological relevance of human papillomaviruses in vulvar cancer.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/28377483" id="rid10" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          11 : Vulvar Squamous Cell Carcinoma (VSCC) as Two Diseases: HPV Status Identifies Distinct Mutational Profiles Including Oncogenic Fibroblast Growth Factor Receptor 3.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/23886586" id="rid11" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          12 : Worldwide human papillomavirus genotype attribution in over 2000 cases of intraepithelial and invasive lesions of the vulva.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/36933562" id="rid12" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          13 : Prevalence of human papillomavirus DNA and p16INK4a positivity in vulvar cancer and vulvar intraepithelial neoplasia: a systematic review and meta-analysis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/21057461" id="rid13" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          14 : Differentiated vulvar intraepithelial neoplasia is often found in lesions, previously diagnosed as lichen sclerosus, which have progressed to vulvar squamous cell carcinoma.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/26974999" id="rid14" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          15 : The Natural History of Vulvar Intraepithelial Neoplasia, Differentiated Type: Evidence for Progression and Diagnostic Challenges.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/7372192" id="rid15" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          16 : The patient-at-risk for development of vulvar cancer.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/5549186" id="rid16" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          17 : Invasive carcinoma of the vulva with lymph node metastasis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/9351758" id="rid17" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          18 : Human papillomavirus type 16 and risk of preinvasive and invasive vulvar cancer: results from a seroepidemiological case-control study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/8990443" id="rid18" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          19 : Human papillomavirus in squamous cell carcinoma of the vulva by polymerase chain reaction.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/11748983" id="rid19" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          20 : Vulvar squamous cell carcinoma in young women: a clinicopathologic study of 21 cases.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15922443" id="rid20" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          21 : Invasive vulvar cancer in a woman with human immunodeficiency virus: case report and review of the literature.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/7791229" id="rid21" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          22 : Prevalence of human papillomavirus in cervical cancer: a worldwide perspective. International biological study on cervical cancer (IBSCC) Study Group.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16368943" id="rid22" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          23 : Clonal history of papillomavirus-induced dysplasia in the female lower genital tract.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15243917" id="rid23" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          24 : A population-based study of vaginal human papillomavirus infection in hysterectomized women.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15790457" id="rid24" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          25 : Vulvar basal cell carcinoma: retrospective study and review of literature.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/10102347" id="rid25" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          26 : Basal cell carcinoma of the vulva.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/9351761" id="rid26" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          27 : Basal cell carcinoma of the vulva: clinical features and treatment results in 28 patients.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/1640707" id="rid27" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          28 : Malignant melanoma of the vulva: a clinicopathologic study of 18 cases.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/17666603" id="rid28" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          29 : Vulvar melanoma: a multivariable analysis of 644 patients.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15589604" id="rid29" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          30 : Population-based incidence rates of malignant melanoma of the vulva in Germany.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/9781962" id="rid30" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          31 : The National Cancer Data Base report on cutaneous and noncutaneous melanoma: a summary of 84,836 cases from the past decade. The American College of Surgeons Commission on Cancer and the American Cancer Society.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/9781962" id="rid31" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          32 : The National Cancer Data Base report on cutaneous and noncutaneous melanoma: a summary of 84,836 cases from the past decade. The American College of Surgeons Commission on Cancer and the American Cancer Society.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/32641392" id="rid32" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          33 : Vulvar sarcoma outcomes by histologic subtype: a Surveillance, Epidemiology, and End Results (SEER) database review.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/26937486" id="rid33" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          34 : Epithelioid sarcoma of the vulva and its clinical implication: A case report and review of the literature.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/28634755" id="rid34" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          35 : Rhabdomyosarcoma of the lower female genital tract: an analysis of 144 cases.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/10739709" id="rid35" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          36 : Paget's disease of the vulva: pathology, pattern of involvement, and prognosis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/29943937" id="rid36" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          37 : Total vaginectomy and radical vulvectomy for extension of extra-mammary Paget's disease.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/9914572" id="rid37" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          38 : Paget's disease of the vulva: prevalence of associated vulvar adenocarcinoma, invasive Paget's disease, and recurrence after surgical excision.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/30458205" id="rid38" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          39 : Vulvar Paget disease: A national retrospective cohort study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/23454498" id="rid39" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          40 : Primary extramammary Paget's disease of the vulva: the clinicopathological features and treatment outcomes in a series of 43 patients.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/21501860" id="rid40" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          41 : Paget's disease of the vulva: Diagnosis and follow-up key to management; a retrospective study of 50 cases from Queensland.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/2162317" id="rid41" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          42 : Vulvar Paget's disease: the need to exclude an invasive lesion.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/35050310" id="rid42" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          43 : Evidence-Based Clinical Practice Guidelines for Extramammary Paget Disease.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/8626099" id="rid43" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          44 : Adenoid cystic carcinoma of Bartholin's gland: a review of the literature and report of a patient.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/8559540" id="rid44" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          45 : Postmenopausal bartholin gland enlargement: a hospital-based cancer risk assessment.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/8384409" id="rid45" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          46 : Carcinomas of Bartholin's gland. Histogenesis and the etiological role of human papillomavirus.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/3010205" id="rid46" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          47 : Bartholin gland carcinoma.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/11531274" id="rid47" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          48 : Bartholin's gland carcinoma: a 15-year experience.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/11277663" id="rid48" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          49 : Primary medical management of recurrent aggressive angiomyxoma of the vulva with a gonadotropin-releasing hormone agonist.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/10561266" id="rid49" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          50 : Conservative treatment for girls with nonmetastatic rhabdomyosarcoma of the genital tract: A report from the Study Committee of the International Society of Pediatric Oncology.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15713139" id="rid50" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          51 : Extramammary Paget's disease.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/37249519" id="rid51" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          52 : Prognostic Analysis of Patients With Extramammary Paget Disease Treated With Conservative Excision.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16803508" id="rid52" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          53 : Paget's disease of the vulva: clinicopathologic study of type 1 cases treated at a single institution.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/12193912" id="rid53" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          54 : Paget's disease of the vulva.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15523356" id="rid54" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          55 : Extramammary Paget's disease: surgical treatment with Mohs micrographic surgery.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/36735397" id="rid55" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          56 : Fluorescein Mapping in Vulvar Paget Disease.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/10651695" id="rid56" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          57 : The Roswell Park Cancer Institute experience with extramammary Paget's disease.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/12828695" id="rid57" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          58 : Comparison of mohs micrographic surgery and wide excision for extramammary Paget's disease.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/2178199" id="rid58" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          59 : Metastatic vulvar Paget's disease responding to combination chemotherapy: case report.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/11161871" id="rid59" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          60 : Radiotherapy with concurrent chemotherapy for vulvar adenocarcinoma associated with extramammary Paget's disease.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/12468332" id="rid60" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          61 : Liposomal doxorubicin for treatment of metastatic chemorefractory vulvar adenocarcinoma.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/18369301" id="rid61" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          62 : Complete resolution of Paget disease of the vulva with imiquimod cream.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/19956374" id="rid62" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          63 : The role of radiation therapy for the extramammary paget's disease of the vulva ; experience of 3 cases.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/19840203" id="rid63" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          64 : Successful treatment of three cases of primary extramammary Paget's disease of the vulva with Imiquimod--proposal of a therapeutic schedule.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/20951507" id="rid64" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          65 : Role of radiotherapy as curative treatment of extramammary Paget's disease.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/34774523" id="rid65" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          66 : Treatment-refractory extramammary Paget disease responsive to radiotherapy.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15491754" id="rid66" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          67 : HER-2/neu expression in Paget disease of the vulva and the female breast.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/20418225" id="rid67" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          68 : HER-2/NEU overexpression in vulvar Paget disease: the Yale experience.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/22053678" id="rid68" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          69 : Adenoid cystic carcinoma of the Bartholin's gland: case report and systematic review of the literature.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/24984535" id="rid69" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          70 : Carcinomas and sarcomas of Bartholin gland. A report of nine cases and review of the literature.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/11321493" id="rid70" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          71 : Advanced primary carcinoma of the Bartholin gland: report of 18 patients.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/10525393" id="rid71" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          72 : Multimodality therapy for carcinoma of the Bartholin gland.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/10739711" id="rid72" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          73 : High-dose-rate interstitial brachytherapy of Bartholin's gland: A case report.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/17504379" id="rid73" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          74 : Primary treatment of Bartholin's gland carcinoma with radiation and chemoradiation: a report on ten consecutive cases.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/12477454" id="rid74" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          75 : Stage IV carcinoma of the Bartholin gland managed with primary chemoradiation.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15882189" id="rid75" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          76 : Adenocarcinoma of mammary-like glands in the vulva successfully treated by weekly paclitaxel.
         </p>
        </a>
       </div>
      </div>
     </div>
    </div>
   </section>
  </section>
  <!-- End Main Menu Area -->
  <!-- Start Search Popup Area -->
  <!-- End Footer Area -->
  <!-- Back to top -->
  <a class="scrolltop" href="#top">
   <i class="icofont-hand-drawn-up">
   </i>
  </a>
  <!-- End Back to top -->
  <!-- jQuery Min JS -->
  <!-- Prpper JS -->
  <!-- Bootstrap Min JS -->
  <!-- Classy Nav Min Js -->
  <!-- Owl Carousel Min Js -->
  <!-- Magnific Popup JS -->
  <!-- CounterUp JS -->
  <!-- Waypoints JS -->
  <!-- Form Validator Min JS -->
  <!-- Contact Form Min JS -->
  <!-- Main JS -->
  <!-- Global site tag (gtag.js) - Google Analytics -->
 </body>
</html>
